Wednesday, December 3, 2008 - 1:25AM EST

Review Articles

21. Myelodysplastic syndromes.

Author
Nimer SD;
Institution
Division of Hematologic Oncology and Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Journal
Blood. 2008 May 15;111(10):4841-51.
Abstract URL
Click here to view abstract

22. Progression of myelodysplasia to acute lymphoblastic leukaemia: implications for disease biology.

Author
Disperati P; Ichim CV; Tkachuk D; Chun K; Schuh AC; Wells RA;
Institution
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, Toronto, Ont., Canada.
Journal
Leuk Res. 2006 Feb;30(2):233-9. Epub 2005 Jul 25.
Abstract URL
Click here to view abstract

23. Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life.

Author
Balducci L;
Institution
Department of Interdisciplinary Oncology, Geriatric Section, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612-9497, USA. balducci@moffitt.usf.edu
Journal
Cancer. 2006 May 15;106(10):2087-94.
Abstract URL
Click here to view abstract

24. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome.

Author
de Lima M; Giralt S;
Institution
Department of Blood and Marrow Transplantation, M.D. Anderson Cancer Center, Houston, TX 77033, USA. mdelima@mdanderson.org
Journal
Semin Hematol. 2006 Apr;43(2):107-17.
Abstract URL
Click here to view abstract

25. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.

Author
Nimer SD; Nimer SD;
Institution
Division of Hematologic Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021-6007, USA. s-nimer@mskcc.org
Journal
J Clin Oncol. 2006 Jun 1;24(16):2576-82.
Abstract URL
Click here to view abstract

26. Myelodysplasia: when to treat and how.

Author
Larson RA;
Institution
Department of Medicine and Cancer Research Center, University of Chicago Pritzker School of Medicine, MC-2115, 5841 S. Maryland Avenue, Chicago, IL 60637, USA. rlarson@medicine.bsd.uchicago.edu
Journal
Best Pract Res Clin Haematol. 2006;19(2):293-300.
Abstract URL
Click here to view abstract

27. The myelodysplastic syndromes: diagnosis and treatment.

Author
Steensma DP; Bennett JM; Steensma DP; Bennett JM;
Institution
Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA. steensma.david@mayo.edu
Journal
Mayo Clin Proc. 2006 Jan;81(1):104-30.
Abstract URL
Click here to view abstract

28. 5-azacytidine and decitabine monotherapies of myelodysplastic disorders.

Author
Kuykendall JR;
Institution
Department of Biomedical and Pharmaceutical Sciences, Raabe College of Pharmacy, Ohio Northern University, Ada, OH 45810-1599, USA. j-kuykendall@onu.edu
Journal
Ann Pharmacother. 2005 Oct;39(10):1700-9. Epub 2005 Sep 6.
Abstract URL
Click here to view abstract

29. Strategies for biology- and molecular-based treatment of myelodysplastic syndromes.

Author
Lindberg EH;
Institution
Karolinska Institutet, Dept of Medicine, Div of Hematology, Karolinska University Hospital Huddinge, 141 86 Stockholm, Sweden. eva.hellstrom-lindberg@medhs.ki.se
Journal
Curr Drug Targets. 2005 Sep;6(6):713-25.
Abstract URL
Click here to view abstract

30. New agents in the treatment of childhood leukemias and myelodysplastic syndromes.

Author
Corey SJ;
Institution
Section of Pediatric Leukemia and Lymphoma, Division of Pediatrics and Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Box 853, 1515 Holcombe Boulevard, Houston, TX 77030, USA. sjcorey@mdanderson.org
Journal
Curr Oncol Rep. 2005 Nov;7(6):399-405.
Abstract URL
Click here to view abstract
Pages: 1 2 3 4 5 6